Promisingly, Hrustanovic et al. 26 have demonstrated in vitro and in vivo that targeting MEK together with ALK in cancer cells harbouring EML4-ALK is highly effective at supressing cell growth compared to inhibition of either target alone. Here, MAP2K7 is linked to cancer.